Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
5-Aminosalicylic acid (5-ASA), also known as mesalamine or mesalazine, is an anti-inflammatory drug primarily used for the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease. Its therapeutic effect relies on targeted delivery to the colon, where it exerts local anti-inflammatory actions.
Inhibition of cyclooxygenase and lipoxygenase, leading to reduced prostaglandin production. Inhibition of thromboxane synthetase, platelet activating factor synthetase, and interleukin-1. Activation of PPAR-γ.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 5-Aminosalicylic Acid (5-ASA).